CADL - Company ID 0001841387
The table below shows Candel Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$38.31M | -$27.02M | -$34.24M | -$31.42M | -$22.22M | -$9.07M |
| Capital expenditure | $587.00K | $16.00K | $457.00K | $1.30M | $1.83M | $1.48M |
| Investing cash flow | -$560.00K | -$16.00K | -$280.00K | -$1.30M | -$1.83M | $38.45M |
| Dividends paid | - | - | - | - |
Candel Therapeutics, Inc. reported operating cash flow of -$38.31M for fiscal year 2025. That is down 41.8% from -$27.02M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$9.07M (FY 2020) to -$38.31M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $56.10M | $94.28M | -$121.00K | $19.97M | $71.80M | $490.00K |